Large-scale study of Moderna COVID-19 vax to be fully enrolled in 4-6 weeks – CEO

In an interview on CNBC this morning, Moderna (NASDAQ:MRNA) CEO Stephane Bancel said that he expects the 30K-subject study assessing mRNA-1273 should be fully enrolled in 4-6 weeks.

Preliminary efficacy data may be available as early as September/October/November depending on the event rate.

Safety is top concern. On the efficacy front, he is confident that mRNA-1273 can meet the FDA threshold of 50% effectiveness compared to control.

Data from non-human primate study will provide additional color on potential efficacy.

https://seekingalpha.com/news/3595143-large-scale-study-moderna-covidminus-19-vaccine-to-be-fully-enrolled-in-4minus-6-weeks-ceo